ADMA Biologics, Inc. (NASDAQ: ADMA) is a Healthcare company (Biotechnology) with a market capitalization of $3.0B. The Maz Rating grades it against the other companies in its sector.
ADMA Biologics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $13.63, ADMA Biologics, Inc. trades at 17.1x trailing earnings, 5.8x sales and 6.9x book value, with an EV/EBITDA of 12.3. Over the last twelve months it generated about $525M of revenue and $177M of net income. It runs a gross margin of 68.5%, an operating margin of 44.9% and a net margin of 35.1%. It shows return on equity of 42.6%, return on invested capital of 28.2% and a free cash flow yield of 4.4%. On the balance sheet: a debt-to-equity ratio of 0.46 and a current ratio of 6.04. Over the past 52 weeks the share price ranged from $7.21 to $20.46, with a beta of 0.77.
ADMA Biologics, Inc. does not currently pay a dividend.
10 Wall Street analyst ratings cover the stock: 1 Strong Buy, 8 Buy and 1 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.